Vectura's collaboration with pharma giant Novartis on developing a generic combination therapy for chronic obstructive pulmonary disease came a step closer to fruition, with the successful completion of the first batch of final-stage trials for Vectura's QVA149 product.
IC TIP:
Buy
at
64p
If further trials and regulatory filings follow as planned then Vectura will see the first milestone payments in 2013.
